/

CAPR

Capricor Therapeutics, Inc.Closed

6.88−0.59 −7.90%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 6.85 −0.44%

Open

7.32

Prev close

7.47

Day range

6.877.40

52-week range

2.9640.37

Volume

2.63M0.38×

Mkt cap

400.00M

P/E ttm

—

Fwd P/E

-4.74

EPS ttm

-2.45

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−82.96%

Price Chart

Yahoo Finance · delayed

CAPROct 13, 2026O 7.32H 7.40L 6.87C 6.88−0.59 (−7.90%)Vol 2.66M

SMA 507.77
SMA 20021.99

1Y change +2.38% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CAPR Capricor Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −11.23%
1 month: −17.80%
3 months: −66.73%
6 months: −80.18%
Year to date: −76.16%
1 year: +2.38%

Valuation & ownership

Market cap: 400.00M
Enterprise value: 253.11M
P/E (ttm): —
Forward P/E: -4.74
PEG ratio: 0.38
Price / book: 1.62
Price / sales (ttm): —
EV / EBITDA: -1.90
EPS (ttm): -2.45
EPS (forward): -1.45
Beta (5y monthly): 0.61
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 58.14M
Float: 42.60M
Short % of float: 35.75%
Short ratio (days): 4.84
Held by insiders: 9.44%
Held by institutions: 76.29%
Avg volume (3m): 6.97M
50-day average: 7.72
200-day average: 22.11
52-week change: +2.38%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 35.4
vs 50-day SMA: −11.46%
vs 200-day SMA: −68.72%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.06%
Realised vol (20d, ann.): 91.9%
From 52-week high: −82.96%
From 52-week low: +132.43%

ANR

Analyst Consensus

5 analysts

Consensus

Buy

2.30 on a 1 (strong buy) – 5 (sell) scale

Mean target

27.00

+292.44% implied

Low 7.00Median 25.00High 54.00

Recommendation trend

Now4 / 6 / 0
1m ago4 / 6 / 0

DES

About Capricor Therapeutics, Inc.

Yahoo Finance profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 231
Headquarters: San Diego, CA, United States
Website: capricor.com
Officers: Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board

SEAS

Seasonality · CAPR

2007–2026 · monthly returns

Strongest month Jan +35.50%Weakest month Nov −11.94%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-24.2	27.6	8.8	10.5	-10.8	-19.6	-84.0	157.4	-4.4	-27.3			−76.2%
2025	9.0	2.3	-38.3	33.8	-22.1	0.4	-17.6	-23.2	14.8	-9.7	-17.8	439.4	+109.1%
2024	-17.4	4.0	61.7	-22.4	7.8	-16.0	-14.9	12.6	232.8	32.1	-5.4	-27.4	+182.2%
2023	9.3	7.8	-7.3	-7.8	16.5	5.5	-7.9	47.3	-47.2	-17.5	5.3	64.6	+26.7%
2022	21.8	13.4	-15.3	-7.6	14.5	-3.9	32.1	26.2	3.1	-7.3	-19.6	-13.6	+31.7%
2021	91.8	-6.7	-23.8	-1.1	-18.1	35.4	-14.8	14.6	-19.8	-7.5	-9.4	-13.1	−14.6%
2020	19.5	-22.9	1.7	483.3	-33.7	-0.9	73.0	-24.2	-12.9	-26.5	8.8	-18.3	+168.0%
2019	24.4	-13.7	6.8	2.1	-35.4	7.1	32.5	-45.9	55.5	-30.8	-39.5	-17.4	−68.8%
2018	26.6	-9.0	-25.3	1.5	-3.6	0.8	-12.7	3.4	-13.2	-11.4	-17.2	-46.8	−74.1%
2017	-8.3	18.9	16.6	-7.7	-73.7	1.2	27.7	-3.8	197.1	-18.2	-24.2	-16.0	−40.6%
2016	-13.0	-7.9	3.3	55.1	-19.0	23.8	-6.3	-1.1	-11.5	-10.2	8.2	-15.6	−13.4%
2015	73.3	-10.5	48.1	-30.7	-1.2	-14.4	-8.9	3.5	-14.9	-2.2	6.6	-27.3	−18.1%
2014	315.4	-13.3	-27.4	-41.3	-3.8	-8.3	-12.5	13.8	-12.1	6.5	-4.4	-4.3	+15.4%
2013	140.0	-25.0	11.1	0.0	-20.0	-37.5	-40.0	66.7	0.0	20.0	-15.0	27.5	+30.0%
2012	-7.3	9.8	-10.7	-46.0	-25.9	-50.0	40.0	-7.1	-15.4	-27.3	-37.5	0.0	−90.9%
2011	-12.9	11.1	36.7	-3.7	-26.6	34.5	-10.3	-7.1	-3.1	-7.9	0.0	-5.2	−11.3%
2010	-3.3	0.9	-16.9	-30.6	-25.0	-35.3	12.1	48.6	14.5	14.3	-27.8	19.2	−48.8%
2009	-16.5	-5.6	-26.9	-20.4	105.1	15.0	106.5	2.1	-15.5	-22.0	5.5	-10.4	+42.4%
2008	-13.6	-5.5	2.4	18.5	-6.4	2.9	-22.9	16.3	-14.4	-58.3	-43.5	-10.5	−84.5%
2007			0.0	-24.0	2.5	0.0	-43.9	78.3	109.8	33.7	0.0	-4.3	+109.1%

INSD

Insider Activity · CAPR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

106.9K shares

Sells, 6 months

114.8K shares

Net shares

−7.8K

Net change in insider shares

−0.10%

Date	Insider	Transaction	Shares	Value
Jun 24, 2026	Krasney KarenGeneral Counsel	Sale at price 30.38 per share.	24.1K	$732.16K
Jun 24, 2026	Bergmann AnthonyChief Financial Officer	Sale at price 30.38 per share.	24.1K	$732.16K
Jun 24, 2026	Krasney KarenGeneral Counsel	Conversion of Exercise of derivative security at price 3.18 per share.	24.1K	$76.64K
Jun 24, 2026	Bergmann AnthonyChief Financial Officer	Conversion of Exercise of derivative security at price 3.18 per share.	24.1K	$76.64K
Jun 23, 2026	Krasney KarenGeneral Counsel	Sale at price 30.00 per share.	900	$27.00K
Jun 23, 2026	Bergmann AnthonyChief Financial Officer	Sale at price 30.00 per share.	900	$27.00K
Jun 23, 2026	Krasney KarenGeneral Counsel	Conversion of Exercise of derivative security at price 3.18 per share.	900	$2.86K
Jun 23, 2026	Bergmann AnthonyChief Financial Officer	Conversion of Exercise of derivative security at price 3.18 per share.	900	$2.86K
May 17, 2026	Bergmann AnthonyChief Financial Officer	Conversion of Exercise of derivative security at price 1.39 per share.	3K	$4.17K
May 12, 2026	Litvack Frank IDirector	Conversion of Exercise of derivative security at price 1.39 per share.	3.9K	$5.47K
Apr 30, 2026	Krasney KarenGeneral Counsel	Sale at price 31.70 per share.	25K	$792.55K
Apr 30, 2026	Bergmann AnthonyChief Financial Officer	Sale at price 31.70 per share.	25K	$792.54K
Apr 30, 2026	Krasney KarenGeneral Counsel	Conversion of Exercise of derivative security at price 3.18 per share.	25K	$79.50K
Apr 30, 2026	Bergmann AnthonyChief Financial Officer	Conversion of Exercise of derivative security at price 3.18 per share.	25K	$79.50K
Apr 1, 2026	Sabar Karimah EsDirector	Sale at price 32.00 per share.	7.5K	$240.93K
Apr 1, 2026	Sabar Karimah EsDirector	Conversion of Exercise of derivative security at price 3.18 per share.	7.5K	$23.94K
Mar 31, 2026	Sabar Karimah EsDirector	Sale at price 30.17 - 31.03 per share.	115K	$3.52M
Mar 31, 2026	Sabar Karimah EsDirector	Conversion of Exercise of derivative security at price 4.86 per share.	115K	$558.90K
Mar 30, 2026	Krasney KarenGeneral Counsel	Sale at price 30.12 per share.	25K	$752.93K
Mar 30, 2026	Bergmann AnthonyChief Financial Officer	Sale at price 30.13 per share.	25K	$753.15K

CAPR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CAPR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Capricor Therapeutics, Inc.

Seasonality · CAPR

Insider Activity · CAPR

Congress Trades · CAPR

Investors Holding CAPR

Investors Holding CAPR

Congress Trades · CAPR

Insider Activity · CAPR

Seasonality · CAPR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Capricor Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News